# Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)

Study · id `cardio:ct-nct04737408` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04737408](<https://clinicaltrials.gov/study/NCT04737408>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04737408

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04737408. Randomized; no masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2023-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04737408, source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)
- Started: 2020-05-13 (actual) (ClinicalTrials.gov record NCT04737408, source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)
- Primary completion: 2023-08 (anticipated) (ClinicalTrials.gov record NCT04737408, source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)
- Completion: 2023-08 (anticipated) (ClinicalTrials.gov record NCT04737408, source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)
- Countries: Denmark (ClinicalTrials.gov record NCT04737408, source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04737408-2021-02-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)
- Acronym: FlowPromote
- Condition: Coronary Artery Disease
- Intervention (Drug): Rosuvastatin 40mg
- Lead sponsor: Bjarne Linde Noergaard
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

## Provenance

Content hash: b6acca96ea1521bee3397eb7d7f507a29d8f6c115bde9146e6423675a3256c48
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
